May be the Game Changers or Not: Kinder Morgan Inc. (KMI) and Regeneron Pharmaceuticals Inc. (REGN)

On Nov 11, KINDER RICHARD D, Executive Chairman bought 300,000 shares of Kinder Morgan Inc. (NYSE: KMI), with the average selling price of the stock being $19.97 per share. The total amount realized from this purchase $5,991,330. A document was filed with the Securities and Exchange Commission to notify the public about the purchase of the shares.

In addition to that, V.P. (Pres.,Nat.Gas Pipelines) – MARTIN THOMAS A sold an extra 20,733 shares of this stock in a transaction that took place a day before, on Nov 04, with a share sold at an average of $20.65 and a total of $428,136 was realized from this transaction. After the transaction, the V.P. (Pres.,Nat.Gas Pipelines) – MARTIN THOMAS A was left with 908,974 shares of the company’s stock, which is currently worth around $18770313.1.

The recent price movement of KMI means that it is now down by -5.93% from its 52-week high and 38.30% up against its 52-week low prices. Over the past one week, the price volatility of KMI stands at 1.48% while the volatility over the past one month is 1.63%. The beta score for this stock is 0.76. A beta score below 1 means that the stock has a low volatility while above 1 signifies that a stock is highly volatile at that particular moment, a data that traders use to keep tabs on their investments.

The company on 08/01/2019 published its latest quarterly earnings, with the report showing that the company recorded 0.25 earnings per share (EPS) during that period. This report was below the expectations of analysts of 0.26 by -0.01. The revenue by the firm was 3.63B for the quarter.

The shares of Kinder Morgan Inc. (KMI) dropped by -0.64%, leading to a loss of -$0.13 per share, and saw KMI end the trading session at $20.22 on Thursday 11/14/19. KMI started the trading session at $20.37, before reaching a daily high of $20.51. It wasn’t able to sustain that growth though and soon jumped to hit a daily low of $20.12.

The trading volume on Thursday stood at 12930231, which was below the stock’s 3-month average volume of 11.46 million shares, out of a total 1.95B shares. As the price of the stock dipped, the market valuation of the company dropped to 45.82 billion.

The shares of Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) went down by -2.85% by the end of the recent trading session. This movement saw its price plunge to close at $338.39, which was lower than the previous closing price of $348.30. Over the past one week, the price of REGN has jumped by 3.68%, while it has recorded a gain of 13.02% over the past one month. Its three-month performance saw REGN gain 13.99% while its six-month performance saw it surge by 10.97%. The situation is different though over the past one year, as the stock price went down by -1.08%, while its year-to-date (YTD) price performance slipped by -9.40%. The stock price has gone up by +24.70% compared to its 90-day low, while it is down -3.32% compared to its 90-day high price.

Let’s take a look at its short, medium and long-term indicators. Composite Indicators shows that Trendspotter rated the stock as a Buy. In the short-term, the stock has a 20-day average volume of 797,575 shares, with the short-term indicators averagely rating the stock as a 50% Buy. A look at its medium-term indicators reveals that it has a 50-Day average volume of 761,254 shares and the indicators have an average rating of 50% Sell. The last indicators, the long-term see REGN stock with a 100-Day average volume of 751,188 shares, giving it an average rating of 50% Buy. A look at the general picture of all short, medium and long-term indicators leaves REGN with an average rating of 24% Buy.

Several brokerage firms sent out their reports REGN stock not long ago. In its report sent out on November 12, 2019, SunTrust lowered its ratings on REGN to a Hold. In an earlier report on November 07, 2019, Citigroup Upgrade the stock from a Neutral to a Buy. BofA/Merrill meanwhile in its report on October 17, 2019 Resumed its rating of the stock to “Neutral”.

In related news to the company’s stock, around 74.00% shares are being held by institutional investors. In a recent SEC filing, the company revealed that 725 institutions currently hold the REGN stock. In the last quarter, a 73,989,141 REGN shares were in the possession of institutions. On the other hand, the company recorded 57 new institutions who bought it their stock, while 87 institutions sold their entire REGN reserve. Of the current institutions investing in the stock, 313 increased their investment while 313 decreased their investment in the stock.